Related Experiment Video

Updated: Jun 23, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Identification of gene defects by linkage analysis: use in inherited cardiomyopathies

H P Vosberg1

  • 1Max-Planck-Institut for Physiological and Clinical Research, Department of Experimental Cardiology, Bad Nauheim, Germany.

European Heart Journal
|December 1, 1994
PubMed

Insights

Researchers are identifying genetic causes for inherited heart conditions like hypertrophic cardiomyopathy (HCM). Discovering these mutations improves diagnosis and guides future therapies for this serious cardiac disorder.

Area of Science:

  • Cardiology
  • Medical Genetics
  • Molecular Biology

Background:

  • Identifying inherited disease causes is crucial for medical and cardiological research.
  • Hypertrophic cardiomyopathy (HCM) is characterized by ventricular wall thickening, arrhythmias, and sudden cardiac death.
  • Molecular causes for some HCM cases have been identified.

Purpose of the Study:

  • To determine the genes and risk factors contributing to inherited cardiac disorders.
  • To advance diagnostic standards and refine therapies for conditions like HCM.
  • To investigate the molecular basis of hypertrophic cardiomyopathy.

Main Methods:

  • Genetic mapping procedures utilizing linkage analysis between clinical phenotype and genomic markers.
  • Identification of point mutations and missense mutations in specific genes.
  • Localization of disease loci on various chromosomes.

Main Results:

  • The first identified cause of HCM was a point mutation in the cardiac beta-myosin heavy chain gene (chromosome 14).
  • Additional missense mutations were found in the beta-myosin globular head.
  • Other disease loci associated with HCM were identified on chromosomes 1, 11, and 15.

Conclusions:

  • Genetic research has identified specific molecular causes for certain types of hypertrophic cardiomyopathy.
  • Further research is needed to determine the disease genes at the identified loci on chromosomes 1, 11, and 15.
  • Understanding the genetic underpinnings of HCM is essential for developing targeted diagnostic and therapeutic strategies.

More Related Videos

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Related Concept Videos

Pedigree Analysis01:35

Pedigree Analysis

Overview
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...